---
title: Platinum-based chemotherapy promotes antigen presenting potential in monocytes
  of patients with high-grade serous ovarian carcinoma
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39315092/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240924183559&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide.
  The major clinical challenge includes the asymptomatic state of the disease, making
  diagnosis possible only at advanced stages. Another OC complication is the high
  relapse rate and poor prognosis following the standard first-line treatment with
  platinum-based chemotherapy. At present, numerous clinical trials are being conducted
  focusing on immunotherapy in OC; nevertheless, there are still no FDA-approved ...
disable_comments: true
---
Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. The major clinical challenge includes the asymptomatic state of the disease, making diagnosis possible only at advanced stages. Another OC complication is the high relapse rate and poor prognosis following the standard first-line treatment with platinum-based chemotherapy. At present, numerous clinical trials are being conducted focusing on immunotherapy in OC; nevertheless, there are still no FDA-approved ...